354 related articles for article (PubMed ID: 27275478)
1. Pancreatic cancer from bench to bedside: molecular pathways and treatment options.
Kosmidis C; Sapalidis K; Kotidis E; Mixalopoulos N; Zarogoulidis P; Tsavlis D; Baka S; Man YG; Kanellos J
Ann Transl Med; 2016 May; 4(9):165. PubMed ID: 27275478
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer: Current research and future directions.
Falasca M; Kim M; Casari I
Biochim Biophys Acta; 2016 Apr; 1865(2):123-32. PubMed ID: 26794394
[TBL] [Abstract][Full Text] [Related]
3. Current standards and new innovative approaches for treatment of pancreatic cancer.
Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
[TBL] [Abstract][Full Text] [Related]
4. Translational research in pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2011 Mar; 12(2):120-2. PubMed ID: 21386635
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge.
Rizwani W; Allen AE; Trevino JG
Cancers (Basel); 2015 Sep; 7(3):1785-805. PubMed ID: 26404380
[TBL] [Abstract][Full Text] [Related]
6. Taking advances from bench to bedside during the last decade.
Kok MR; Tak PP
Best Pract Res Clin Rheumatol; 2012 Apr; 26(2):225-36. PubMed ID: 22794095
[TBL] [Abstract][Full Text] [Related]
7. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
Gautam SK; Kumar S; Dam V; Ghersi D; Jain M; Batra SK
Semin Immunol; 2020 Feb; 47():101391. PubMed ID: 31952903
[TBL] [Abstract][Full Text] [Related]
8. Advances in early diagnosis and therapy of pancreatic cancer.
Xu Q; Zhang TP; Zhao YP
Hepatobiliary Pancreat Dis Int; 2011 Apr; 10(2):128-35. PubMed ID: 21459718
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
10. Advanced stage pancreatic cancer: novel therapeutic options.
Saif MW
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):487-98. PubMed ID: 24939470
[TBL] [Abstract][Full Text] [Related]
11. Precision Therapy of Pancreatic Cancer: From Bench to Bedside.
Ciecielski KJ; Berninger A; Algül H
Visc Med; 2020 Oct; 36(5):373-380. PubMed ID: 33178734
[TBL] [Abstract][Full Text] [Related]
12. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
[TBL] [Abstract][Full Text] [Related]
13. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside.
Uddin MH; Al-Hallak MN; Philip PA; Mohammad RM; Viola N; Wagner KU; Azmi AS
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204940
[TBL] [Abstract][Full Text] [Related]
14. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options.
Zhang CY; Liu S; Yang M
World J Gastroenterol; 2022 Dec; 28(48):6827-6845. PubMed ID: 36632312
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered mouse models of pancreatic cancer.
Westphalen CB; Olive KP
Cancer J; 2012; 18(6):502-10. PubMed ID: 23187836
[TBL] [Abstract][Full Text] [Related]
16. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.
Yang F; Jin C; Jiang Y; Li J; Di Y; Ni Q; Fu D
Cancer Treat Rev; 2011 Dec; 37(8):633-42. PubMed ID: 21330062
[TBL] [Abstract][Full Text] [Related]
17. Current and future intratumoral targeted treatment for pancreatic cancer.
Zarogoulidis P; Pavlioglou P; Pivert PL; Machairiotis N; Katsikogiannis N; Kougioumtzi I; Tsimogiannis K; Kakolyris S; Courcoutsakis N; Tsiouda T; Sakkas A; Makrantonaki D; Zarogoulidis K
Ther Deliv; 2014 Aug; 5(8):913-26. PubMed ID: 25337648
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for the treatment of adenocarcinoma of the pancreas.
Mackenzie RP; McCollum AD
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1473-85. PubMed ID: 19828009
[TBL] [Abstract][Full Text] [Related]
19. Drugs in preclinical and early-stage clinical development for pancreatic cancer.
Asuthkar S; Rao JS; Gondi CS
Expert Opin Investig Drugs; 2012 Feb; 21(2):143-52. PubMed ID: 22217246
[TBL] [Abstract][Full Text] [Related]
20. A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
Mountzios G; Syrigos KN
Drug Saf; 2011 Mar; 34(3):175-86. PubMed ID: 21332242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
